On July 19, 2017, Dar Bioscience, Inc. completed its business combination with Dar Bioscience Operations, Inc. On July 19, 2017, in connection with the completion of the Dar Transaction, Christopher D.T. Guiffre, Stuart A. Arbuckle, Alan L. Crane, David R. Parkinson, David R. Walt, Paul A. Friedman and William T. McKee resigned from the Board of Directors of the Daré Bioscience, Inc. and Sabrina Martucci Johnson, Roger L. Hawley and Robin J. Steele were each appointed to the Board of Directors. In accordance with the Dar Stock Purchase Agreement, the company's Board of Directors and its committees were reconstituted, with Susan L. Kelley, M.D. appointed as a Class I director of the Company whose term expires at the company's 2018 annual meeting of stockholders, William H. Rastetter, Ph.D. and Robin J. Steele appointed as Class II directors of the company whose terms expire at the company's 2019 annual meeting of stockholders and Sabrina Martucci Johnson and Roger L. Hawley appointed as Class III directors of the company whose terms expire at the company's 2020 annual meeting of stockholders (with Mr.Hawley appointed to serve as Chairman of the Board of Directors). In addition, Dr. Rastetter, Ms. Steele and Mr. Hawley were appointed to the Company's Audit Committee (with Mr. Hawley appointed to serve as chair of the committee); Dr. Rastetter and Ms. Steele were appointed to the company's Compensation Committee (with Dr. Rastetter appointed to serve as chair of the committee); and Mr. Hawley and Dr. Kelley were appointed to the Nominating and Corporate Governance Committee (with Dr. Kelley appointed to serve as chair of the committee). The Board of Directors has determined that Drs. Kelley and Rastetter, Ms. Steele and Mr. Hawley are independent as contemplated by the rules of the NASDAQ Stock Market and other governing laws and applicable regulations.
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
DARÉ BIOSCIENCE, INC. 
